Infectious diseases

Nature Reviews Drug Discovery

Volumn 3, Issue 7, 2004, Pages S26-S32

  Labonte, Jason ^a   Lebbos, John ^a   Raja, Aarti ^a   Kirkpatrick, Peter ^a  

^a Decision Resources Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; CEPHALOSPORIN DERIVATIVE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; GEMIFLOXACIN; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LINEZOLID; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; ORITAVANCIN; PENICILLIN G; RITONAVIR; SAQUINAVIR; SERTACONAZOLE; STAVUDINE; STREPTOGRAMIN; VANCOMYCIN; ZIDOVUDINE;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; DNA SYNTHESIS INHIBITION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INJECTION SITE; INJECTION SITE REACTION; MYCOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TINEA PEDIS; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 4043097793     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1409     Document Type: Article

References (30)

1. Pomerantz, R. J. and Horn, D. L. : Twenty years of therapy for HIV-1 infection. Nature Med. 9, 867-873 (2003).
2. De Clercq, E.: Strategies in the design of antiviral drugs. Nature Rev. Drug Disc. 1, 13-25 (2002).
3. Wild, C. T: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl Acad. Sci. USA 91, 9770-9774 (1994).
4. Kilby, J. M.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4, 1302-1307 (1998).
5. FDA Drug Approvals List [online] (cited 14 April 2004) (2003).
6. Lalezari, J. P.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348, 2175-2185 (2003).
7. Lazzarin, A.: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348, 2186-2195 (2003).
8. Carr, A.: Toxicity of antiretroviral therapy and implications for drug development. Nature Rev. Drug Disc. 2, 624-634 (2003).
9. Fassler, A.: Aza-peptide analogues as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability. J. Med. Chem. 39, 3203-3216 (1996).
10. Priestle, J. P: Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Structure 3, 381-389 (1995).
11. Bold, G.: New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 41, 3387-3401 (1998).
12. Robinson, B. S.: BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44, 2093-2099 (2000).
13. FDA Drug Approvals List [online] (cited 14 April 2004). (2003).
14. Coates, A.: The future challenges facing the development of new antimicrobial drugs. Nature Rev. Drug Disc. 1,895-910 (2002).
15. Walsh, C.: Where will new antibiotics come from? Nature Rev. Microbiol. 1, 65-69 (2003).
16. Lowy, F D.: Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 111, 1265-1273 (2003).
17. Tally, F P and DeBruin, M. F: Development of daptomycin for Gram-positive infections. J. Antimicrob. Chemother. 46, 523-526 (2000).
18. FDA Drug Approvals List [online] (cited 14 April 2004). (2003).
19. Debono, M.: Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J. Antibiot. (Tokyo) 41, 1093-1105 (1988).
20. Fuchs, P C.: In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49, 467-470 (2002).
21. Appelbaum, P C. and Hunter, P A.: The fluoroquinolone antibacterials: past, present and future perspectives. Intl J. Antimicrob. Agents 16, 5-15 (2000).
22. Hong, C. Y.: Discovery of gemlfloxacin (Factlve, LB20304a): a qulnolone of a new generation. Il Farmaco 56, 41-44 (2001).
23. FDA Drug Approvals List [online] (cited 14 April 2004). (2003).
24. Schinazi, R. F.: Selective inhibition of human immuno¬deficiency viruses by racemates and enantiomers of cis-5- fluoro-1-(2-hydroxy-methyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36, 2423-2431 (1992).
25. Richman, D. D.: Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antiviral Ther. 6, 83-88 (2001).
26. FDA Drug Approvals List [online] (cited 14 April 2004). (2003).
27. Hainer, B. L.: Dermatophyte infections. Am. Fam. Physician 67, 101-108 (2003).
28. Odds, F C.: Antifungal agents: mechanisms of action. Trends Microbiol. 11,272-279 (2003).
29. FDA Drug Approvals List [online] (cited 14 April 2004). (2003).
30. Carrillo-Munoz, A. J.: In vitro antifungal activity of sertaconazole against 309 dermatophyte clinical isolates.J. Chemother. 15, 555-557 (2003).